General Information of Drug Off-Target (DOT) (ID: OT0AS010)

DOT Name Mitogen-activated protein kinase 11 (MAPK11)
Synonyms MAP kinase 11; MAPK 11; EC 2.7.11.24; Mitogen-activated protein kinase p38 beta; MAP kinase p38 beta; p38b; Stress-activated protein kinase 2b; SAPK2b; p38-2
Gene Name MAPK11
UniProt ID
MK11_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
3GC8; 3GC9; 3GP0
EC Number
2.7.11.24
Pfam ID
PF00069
Sequence
MSGPRAGFYRQELNKTVWEVPQRLQGLRPVGSGAYGSVCSAYDARLRQKVAVKKLSRPFQ
SLIHARRTYRELRLLKHLKHENVIGLLDVFTPATSIEDFSEVYLVTTLMGADLNNIVKCQ
ALSDEHVQFLVYQLLRGLKYIHSAGIIHRDLKPSNVAVNEDCELRILDFGLARQADEEMT
GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLQGKALFPGSDYIDQLKRIMEVVG
TPSPEVLAKISSEHARTYIQSLPPMPQKDLSSIFRGANPLAIDLLGRMLVLDSDQRVSAA
EALAHAYFSQYHDPEDEPEAEPYDESVEAKERTLEEWKELTYQEVLSFKPPEPPKPPGSL
EIEQ
Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK11 functions are mostly redundant with those of MAPK14. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Additional examples of p38 MAPK substrates are the FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates NLRP1 downstream of MAP3K20/ZAK in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis.
Tissue Specificity Highest levels in the brain and heart. Also expressed in the placenta, lung, liver, skeletal muscle, kidney and pancreas.
KEGG Pathway
Endocrine resistance (hsa01522 )
MAPK sig.ling pathway (hsa04010 )
Rap1 sig.ling pathway (hsa04015 )
FoxO sig.ling pathway (hsa04068 )
Sphingolipid sig.ling pathway (hsa04071 )
Oocyte meiosis (hsa04114 )
Efferocytosis (hsa04148 )
Cellular senescence (hsa04218 )
Adrenergic sig.ling in cardiomyocytes (hsa04261 )
VEGF sig.ling pathway (hsa04370 )
Osteoclast differentiation (hsa04380 )
Sig.ling pathways regulating pluripotency of stem cells (hsa04550 )
Platelet activation (hsa04611 )
Neutrophil extracellular trap formation (hsa04613 )
Toll-like receptor sig.ling pathway (hsa04620 )
NOD-like receptor sig.ling pathway (hsa04621 )
RIG-I-like receptor sig.ling pathway (hsa04622 )
C-type lectin receptor sig.ling pathway (hsa04625 )
IL-17 sig.ling pathway (hsa04657 )
Th1 and Th2 cell differentiation (hsa04658 )
Th17 cell differentiation (hsa04659 )
T cell receptor sig.ling pathway (hsa04660 )
Fc epsilon RI sig.ling pathway (hsa04664 )
TNF sig.ling pathway (hsa04668 )
Leukocyte transendothelial migration (hsa04670 )
Thermogenesis (hsa04714 )
Neurotrophin sig.ling pathway (hsa04722 )
Retrograde endocan.binoid sig.ling (hsa04723 )
Dopaminergic sy.pse (hsa04728 )
Inflammatory mediator regulation of TRP channels (hsa04750 )
GnRH sig.ling pathway (hsa04912 )
Progesterone-mediated oocyte maturation (hsa04914 )
Prolactin sig.ling pathway (hsa04917 )
Relaxin sig.ling pathway (hsa04926 )
Non-alcoholic fatty liver disease (hsa04932 )
AGE-RAGE sig.ling pathway in diabetic complications (hsa04933 )
Growth hormone synthesis, secretion and action (hsa04935 )
Alcoholic liver disease (hsa04936 )
Amyotrophic lateral sclerosis (hsa05014 )
Prion disease (hsa05020 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Epithelial cell sig.ling in Helicobacter pylori infection (hsa05120 )
Pathogenic Escherichia coli infection (hsa05130 )
Shigellosis (hsa05131 )
Salmonella infection (hsa05132 )
Pertussis (hsa05133 )
Yersinia infection (hsa05135 )
Leishmaniasis (hsa05140 )
Chagas disease (hsa05142 )
Toxoplasmosis (hsa05145 )
Tuberculosis (hsa05152 )
Hepatitis B (hsa05161 )
Human cytomegalovirus infection (hsa05163 )
Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
Epstein-Barr virus infection (hsa05169 )
Human immunodeficiency virus 1 infection (hsa05170 )
Coro.virus disease - COVID-19 (hsa05171 )
Proteoglycans in cancer (hsa05205 )
Chemical carcinogenesis - reactive oxygen species (hsa05208 )
PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
Diabetic cardiomyopathy (hsa05415 )
Lipid and atherosclerosis (hsa05417 )
Fluid shear stress and atherosclerosis (hsa05418 )
Reactome Pathway
p38MAPK events (R-HSA-171007 )
ERK/MAPK targets (R-HSA-198753 )
Activation of PPARGC1A (PGC-1alpha) by phosphorylation (R-HSA-2151209 )
Oxidative Stress Induced Senescence (R-HSA-2559580 )
DSCAM interactions (R-HSA-376172 )
VEGFA-VEGFR2 Pathway (R-HSA-4420097 )
activated TAK1 mediates p38 MAPK activation (R-HSA-450302 )
Activation of the AP-1 family of transcription factors (R-HSA-450341 )
KSRP (KHSRP) binds and destabilizes mRNA (R-HSA-450604 )
Myogenesis (R-HSA-525793 )
RHO GTPases Activate NADPH Oxidases (R-HSA-5668599 )
Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756 )
NOD1/2 Signaling Pathway (R-HSA-168638 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 3 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Dexamethasone DMMWZET Approved Mitogen-activated protein kinase 11 (MAPK11) increases the Apoptosis ADR of Dexamethasone. [20]
Adenosine DMM2NSK Approved Mitogen-activated protein kinase 11 (MAPK11) increases the Pain ADR of Adenosine. [20]
Afimoxifene DMFORDT Phase 2 Mitogen-activated protein kinase 11 (MAPK11) decreases the response to substance of Afimoxifene. [21]
------------------------------------------------------------------------------------
3 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the methylation of Mitogen-activated protein kinase 11 (MAPK11). [1]
Ciclosporin DMAZJFX Approved Ciclosporin decreases the methylation of Mitogen-activated protein kinase 11 (MAPK11). [2]
Genistein DM0JETC Phase 2/3 Genistein decreases the phosphorylation of Mitogen-activated protein kinase 11 (MAPK11). [12]
------------------------------------------------------------------------------------
17 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Cisplatin DMRHGI9 Approved Cisplatin increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [3]
Estradiol DMUNTE3 Approved Estradiol increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [4]
Quercetin DM3NC4M Approved Quercetin increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [5]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide increases the activity of Mitogen-activated protein kinase 11 (MAPK11). [6]
Calcitriol DM8ZVJ7 Approved Calcitriol increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [7]
Testosterone DM7HUNW Approved Testosterone increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [7]
Triclosan DMZUR4N Approved Triclosan increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [8]
Methotrexate DM2TEOL Approved Methotrexate increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [9]
Selenium DM25CGV Approved Selenium increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [10]
Obeticholic acid DM3Q1SM Approved Obeticholic acid decreases the expression of Mitogen-activated protein kinase 11 (MAPK11). [11]
Tocopherol DMBIJZ6 Phase 2 Tocopherol increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [10]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [13]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 decreases the expression of Mitogen-activated protein kinase 11 (MAPK11). [14]
SB 203580 DMAET6F Terminated SB 203580 decreases the expression of Mitogen-activated protein kinase 11 (MAPK11). [15]
Acetaldehyde DMJFKG4 Investigative Acetaldehyde increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [17]
ELLAGIC ACID DMX8BS5 Investigative ELLAGIC ACID increases the expression of Mitogen-activated protein kinase 11 (MAPK11). [18]
Oxindole 94 DMPFD6Y Investigative Oxindole 94 decreases the activity of Mitogen-activated protein kinase 11 (MAPK11). [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Drug(s)
1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT
Drug Name Drug ID Highest Status Interaction REF
Formaldehyde DM7Q6M0 Investigative Formaldehyde affects the localization of Mitogen-activated protein kinase 11 (MAPK11). [16]
------------------------------------------------------------------------------------

References

1 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
2 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
3 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
4 Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells. J Signal Transduct. 2012;2012:204236. doi: 10.1155/2012/204236. Epub 2012 Oct 9.
5 Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells. BMC Complement Altern Med. 2016 Aug 11;16(1):281. doi: 10.1186/s12906-016-1267-x.
6 Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002 Nov 22;277(47):44988-95. doi: 10.1074/jbc.M207176200. Epub 2002 Sep 17.
7 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
8 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
9 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
10 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
11 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
12 Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact. 2009 Jul 15;180(2):143-50. doi: 10.1016/j.cbi.2009.03.020. Epub 2009 Apr 5.
13 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
14 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
15 Cadmium effects on p38/MAPK isoforms in MDA-MB231 breast cancer cells. Biometals. 2010 Feb;23(1):83-92. doi: 10.1007/s10534-009-9268-6. Epub 2009 Sep 15.
16 Oncoprotein SET dynamically regulates cellular stress response through nucleocytoplasmic transport in breast cancer. Cell Biol Toxicol. 2023 Aug;39(4):1795-1814. doi: 10.1007/s10565-022-09784-4. Epub 2022 Dec 19.
17 Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
18 In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol. 2013 Sep;59:428-37. doi: 10.1016/j.fct.2013.06.025. Epub 2013 Jun 26.
19 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
20 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
21 High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63.